<?xml version="1.0" encoding="UTF-8"?>
<p id="p0115">Multiple clinical trials are underway on the use of remdesivir for treatment of COVID-19 [
 <xref rid="bb0205" ref-type="bibr">41</xref>]. The NIH-sponsored clinical trial, ongoing in the U.S. and the Republic of Korea, is a double-blinded, placebo-controlled trial in which patients are randomized to receive either placebo or an initial dose of 200 mg of intravenous remdesivir on the first day, followed by a maintenance dose of 100 mg per day, through discharge up to a maximum of 10 total treatment days [
 <xref rid="bb0100" ref-type="bibr">20</xref>]. The primary outcome of the trial, as described in the U.S. National Library of Medicine clinical trials registry, will be expressed as the proportion of patients in each category of a seven-category clinical severity scale on the fifteenth day post treatment initiation (
 <xref rid="t0010" ref-type="table">Table 2</xref>) [
 <xref rid="bb0210" ref-type="bibr">42</xref>]. Additionally, Gilead Sciences is sponsoring a remdesivir study among patients with severe COVID-19 with a composite primary outcome measure of fever normalization and oxygen normalization [
 <xref rid="bb0215" ref-type="bibr">43</xref>].
</p>
